NCT05498220View on ClinicalTrials.gov

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

March 7, 2025

Study Completion Date

November 7, 2026

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Polatuzumab vedotin (PV)

1.8 mg/kg, intravenous, at day 1, in every 21 days

DRUG

Rituximab

375 mg/m2 intravenous, at day 1 or day 2, in every 21 days

DRUG

Hyaluronidase

1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days

DRUG

Gemcitabine

1,000 mg/m2 intravenous at day 1 and 8, in every 21 days

DRUG

Cisplatin

75 mg/m2, intravenous, at day 1, in every 21 days

DRUG

Dexamethasone

40 mg intravenous at day 1, Per oral days at days 2-4

DRUG

GCSF

granulocyte-colony stimulating factor (GCSF )

Trial Locations (1)

27514

Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER